Takeda’s Alunbrig scores nod for earlier lung cancer use, but a Roche showdown awaits – FiercePharma

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive non-small cell lung cancer. But there’s plenty of competition waiting to greet it at the door.

The FDA approved the Takeda med Friday based on results from a phase 3 trial showing Alunbrig could cut patients’ risk of disease progression or death by 51% compared with Pfizer’s Xalkori at the 25-month treatment mark.

RELATED: Takeda eyes Alunbrig earlier lung cancer use as 2-year data trounce Pfizer’s Xalkori

Webinar

Bioavailability Enhancement – Industry Insights, Key Challenges & Advanced Development Solutions

Join this webcast on Tuesday, June 16 as experts present the exclusive survey findings and introduce innovative scalable drug delivery technologies proven to address the industry’s growing need for improving solubility and enhancing bioavailability.

And in the population of patients with brain metastases—who make up about 30% to 40% of the ALK-positive pool—the drug cut the risk of brain disease progression by 69%. At the two-year mark, median progression-free survival hadn’t been reached, while Xalkori suppressed tumor growth for just 5.9 months.

“We’re extremely proud of the positive results Alunbrig has shown for newly diagnosed ALK-positive NSCLC patients, particularly those with brain metastases,” Teresa Bitetti, president of Takeda’s global oncology business unit, said in a statement.

The green light is a big break for Alunbrig, which has until now been confined to later lines of therapy. For Takeda’s 2019 fiscal year, the drug pulled in ¥7.2 billion ($66.9 million).

RELATED: ASCO: Roche’s Alecensa stays on top of Xalkori with long-term survival showing

The thing is, Xalkori is no longer the drug to beat in first-line, ALK-positive NSCLC after 2017 go-aheads for Roche’s Alecensa and Novartis’ Zykadia. Of those two, it’s Alecensa that’s run away with the market, generating CHF 876 million ($906 million) in 2019 on the back of data showing it could slash the risk of disease worsening or death by more than 53% against Xalkori.

And recently, Alecensa turned up more data that could help keep it on top. The drug showed it could help patients live longer, with 62.5% of Alecensa patients still alive at the five-year mark versus just 45.5% of the Xalkori group.

Read more on

Source: https://www.fiercepharma.com/pharma/takeda-s-alunbrig-scores-nod-for-earlier-lung-cancer-use-but-a-roche-showdown-awaits